Targeting ER-Positive Breast Cancer: Clinical Application of New Advances in Community Practice

Join us for a live CME/CNE/CPE-certified webinar on managing hormone receptor–positive early and advanced/metastatic breast cancer. Our expert faculty will discuss strategies for selecting optimal therapies, approved and emerging therapies, and approaches for managing adverse events and promoting adherence for oral therapies. Sign up today!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Welcome and Introduction
  • Selection and Sequencing of Targeted Therapy for HR+/HER2- Early-Stage Breast Cancer - Sara Hurvitz, MD, FACP
  • Selection and Sequencing of Targeted Therapy for HR+/HER2- Advanced and Metastatic Breast Cancer - Sara Hurvitz, MD, FACP
  • Managing Adverse Events & Strategies for Promoting Adherence - Jamie Carroll, APRN, CNP, MSN
  • Question and Answer Session

Faculty

Faculty
Jamie Carroll, APRN, CNP, MSN

Faculty
Sara Hurvitz, MD, FACP

Professor of Medicine
Director, 
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with HR+ HER2- BC.

Target Audience
This program is intended for community medical oncologists, nurses, pharmacists, and other HCPs who treat and manage patients with HR+/HER2- breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Address gaps in patient-provider knowledge and perceptions about targeted oral therapies for HR+/HER2- EBC and ABC
  • Foster collaborative discussions between patients/caregivers and providers on guidelines and recent clinical evidence to guide personalized treatment planning for HR+/HER2- EBC and ABC
  • Recognize and manage adverse events associated with CDK4/6 and PI3K inhibitors as well as novel SERD therapies
  • Implement resources to engage patients in shared decision making about approved and investigational treatment options for HR+/HER2- EBC and ABC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-155-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.